Ionis Pharmaceuticals (IONS) Cash from Investing Activities (2009 - 2026)

Ionis Pharmaceuticals' Cash from Investing Activities history runs 18 years deep, the most recent figure standing at $23.5 million for Q2 2026.

• In Q2 2026, Cash from Investing Activities rose 119.57% year-over-year to $23.5 million; the TTM figure through Jun 2026 stood at $232.2 million (up 204.48% YoY), while the FY2025 annual figure was -$277.8 million, down 107.25% from the prior year.
• Cash from Investing Activities for Q2 2026 stood at $23.5 million, down from $536.8 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $536.8 million in Q1 2026, with the low at -$419.5 million in Q4 2025.
• The 5-year median for Cash from Investing Activities is $43.0 million (2024), against an average of -$18.2 million.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities surged 2203.96% in 2023, then sank 714.99% in 2025.
• Ionis Pharmaceuticals' Cash from Investing Activities stood at $212.1 million in 2022, then slumped by 112.59% to -$26.7 million in 2023, then jumped by 355.36% to $68.2 million in 2024, then tumbled by 714.99% to -$419.5 million in 2025, then surged by 105.6% to $23.5 million in 2026.
• Business Quant data shows IONS's Cash from Investing Activities at $23.5 million in Q2 2026, $536.8 million in Q1 2026, and -$419.5 million in Q4 2025.